The global HIV-1 pandemic comprises many genetically divergent subtypes. Most of our un-2 derstanding of drug resistance in HIV-1 derives from subtype B, which predominates in North 3 America and western Europe. However, about 90% of the pandemic represents non-subtype B 4 infections. Here, we use deep sequencing to analyze HIV-1 from infected individuals in Uganda 5 who were either treatment-naïve or who experienced virologic failure on ART without the expected 6 patterns of drug resistance. Our objective was to detect potentially novel associations between mu-7 tations in HIV-1 integrase and treatment outcomes in Uganda, where most infections are subtypes 8 A or D. We retrieved a total of 380 archived plasma samples from patients at the Joint Clinical 9
Introduction 1
There are currently six classes of antiretroviral drugs approved for treatment of HIV-1 infection, oDrop spectrophotometer (Thermo Scientific). The presence of the mutation in the generated plas-1 mid was confirmed by sequencing. Chimeric pREC NFL INT plasmids were co-transfected into 2 HEK293T cells (3 × 10 4 cells/well) along with the complementing plasmid pCMV cplt using Fu-3 gene 6 reagent (Promega, Madison, WI) as described previously [44] . Virus was then propagated 4 on U87.CD4.CXCR4 cells as described [44] . 5 Drug susceptibility assay in TZM-bl cells 6 HIV susceptibility to DTG and RAL was determined using TZM-bl cells. Briefly, 20,000 cells per 7 well were exposed to wildtype (WT), I203M or I208L HIV-1 in presence of 10-fold dilutions of 8 DTG or RAL (100 µM to 10 −7 µM) and DEAE-dextran (1mg/ml) in 96-well tissue culture plates 9 (Corning). The amount of virus added to each well was normalised to a multiplicity of infection 10 (MOI) of 0.01 based on the infectious titer. After 48 hr incubation at 37 • C and 5% CO 2 , the infec-11 tivity of viruses was quantified by staining the cells with X-gal as described previously [45] and 12 then counting the cells using an ImmunoSpot reader. The fold changes in the effective concentra-13 tions for 50% inhibition (EC 50 ) and standard errors of the mean (SEM) were calculated based on 14 two sets of experiments, each performed in quadruplicate. Drug sensitivity curves were generated 15 using nonlinear regression curve fitting features of GraphPad Prism 8.0 software (GraphPad Soft- 16 ware, Inc., San Diego, CA). Drug resistance is presented as fold change in EC 50 between WT and 17 mutant viruses. 18 Sequence analysis 19 We processed the FASTQ files generated by the Illumina MiSeq platform using a customized 20 version of the MiCall pipeline (https://github.com/PoonLab/MiCall-Lite) [17] . First, the pipeline 21 extracts the empirical φ X174 error rates from the 'ErrorMetricsOut' binary InterOp file associ-22 ated with the MiSeq run, and then censors bases in the FASTQ files associated with problematic 23 cycle-tile combinations with error rates exceeding a cutoff of 7.5%. Next, the program cutadapt 24 (version 1.11) [46] was used to filter the FASTQ read data for Illumina adapter sequences. The 25 pipeline subsequently used the alignment program Bowtie2 (version 2.2.6) [47] to map the paired-26 end read data to the full-length sequence encoding HIV-1 integrase of the HXB2 reference genome 27 (Genbank accession K03455). This preliminary mapping stage was followed by the iterative re-28 mapping of reads from the original FASTQ files to new reference sequences, which were progres-1 sively updated with the plurality consensus of reads that were successfully mapped in the previous 2 iteration [17] . A mapping quality score cutoff of Q = 20 was applied at this stage to filter ambigu-3 ously mapped reads. The primary outputs of the pipeline included the sample-specific nucleotide 4 consensus sequence, coverage maps, and the matrix of amino acid frequencies in the coordinate 5 system of the HXB2 reference; insertions relative to this reference coordinate system were written 6 to a separate output file. 7 We used a Python script to filter the amino acid frequency matrices generated by the pipeline 8 described above, using a minimum coverage threshold of at least 1,000 mapped reads per amino 9 acid. First, any matrix corresponding to a pair of FASTQ files was discarded if the overall number 10 of reads mapped to the sample-specific consensus sequence was below this threshold. Next, any 11 individual amino acid position below this coverage threshold was coded as missing data in the 12 remaining frequency matrices. Additionally, any sites with discordant amino acid frequencies 13 within the overlapping region of the two amplicons -i.e., where the frequency of an amino acid 14 exceeded the threshold in one amplicon but not the other -was also coded as missing data. Next, 15 the script converted the amino acid frequency data for each sample into a long binary vector that 16 indicated whether each of the 20 amino acids was observed above a frequency threshold of 1% 17 at every position in the integrase gene; these outputs are herein denoted the low-threshold (LT) 18 data set. This dichotomization step was repeated at a frequency threshold at 20% to produce the 19 high-threshold (HT) data set. Hence, the amino acid frequency data from the aligned short reads 20 were encoded into two presence-absence matrices, each comprising 20 × 288 = 5, 760 variables 21 (columns) and one row for every pair of FASTQ files. Similar dichotomization approaches (e.g., sparse binary encoding [18]) have previously been used for feature selection analyses involving 23 amino acid polymorphisms [18, 48] . All subsequent analyses were replicated across these two 24 data sets.
25

Data imputation 26
A substantial number of patient samples ( Supplementary Table S1 ) were sequenced more than 27 once on the MiSeq platform to take advantage of the large number of index combinations and 28 sequencing yield of this instrument. In other words, the number of rows in the presence-absence 29 matrix produced by the previous step was greater than the number of patient samples. To incorpo-1 rate the entire data collection without unnecessarily and arbitrarily discarding or pooling repeated 2 measurements, we randomly down-sampled redundant rows to obtain a reduced presence-absence 3 matrix with one row per sample, and repeated this procedure to yield 10 replicate matrices. All 4 subsequent analyses were replicated across these matrices.
5
The next stage of our analysis employed a support vector machine (SVM) classifier to identify 6 putative associations between amino acid polymorphisms and RAL failure. Although extensions 7 of SVMs have recently been developed to handle missing data [49] , the prevailing approach is to 8 use a generic method to impute missing values prior to the SVM analysis. We used multivariate 9 imputation by chained equations as implemented in the R package mice [50]. Based on the overall 10 proportion of missing observations in our data sets (3.2% for the LT data set and 2.9% for the HT 11 data set), the recommended minimum number of imputations was 3 [51]. We decided to generate 12 5 imputed data sets for each of the 10 normalized data sets from the previous section. Further, we 13 duplicated this approach for the LT and HT data sets for a total of 5 × 10 × 2 = 100 imputed data 14 sets. To speed up the multivariate imputation, we used the quickpred variable selection procedure 15 implemented in the mice package to filter the data for potentially significant predictors based on a 16 simple correlation statistic. We excluded sites with an absolute correlation with the group labels 17 below 50% and output the remaining variables to a preliminary predictor matrix. Each imputation 18 was run for 20 iterations instead of the default 5 iterations, and convergence was visually assessed 19 using the trace line plots of estimates against iteration numbers. To increase the robustness of 20 results from the SVM analysis, we filtered amino acid features with non-zero weights (based on 21 their incorporation into support vectors) by a minimum frequency of 80% across imputations, i.e.,
22
at least 40 out of 50.
23
SVM analysis 24
The preceding imputation step yielded 100 large presence-absence matrices encoding the observed 25 HIV-1 integrase amino acid polymorphisms across baseline and treatment failure samples. We To calibrate the λ tuning parameter of the SVM model, which controls the severity of penalizing 10 data points that cross the margin of the hyperplane, we used a discrete grid search to determine the 11 optimal λ with minimal misclassification error by 5-fold cross-validation [55] . After training and 12 cross-validation, we generated the final SVM model for the entire data set using the optimized λ 13 parameter. For each of the 100 data sets, we extracted the average feature weights and counts from 14 the SVM results.
15
To corroborate the assignments of the most positive or negative feature weights to specific 16 amino acids per treatment group, we calculated the odds ratios to quantify the statistical associ-17 ations between the amino acid and outcomes (group labels). We calculated odds ratios and 95% 18 confidence intervals by unconditional maximum likelihood estimation (Wald method) as imple-19 mented in the R package epitools, adding a fixed n = 0.5 value to every single cell of its contin-20 gency table to avoid a division by zero error (Haldane-Anscombe correction [56]). Subsequently, 21 we averaged the results for each feature across all 100 data sets. Additional details on the sequence 22 processing and SVM analysis are provided as Supplementary Text S1.
23
Drug resistance prediction 24
To obtain resistance predictions from the sequence data from the IN coding region, we generated 25 a consensus sequence at a polymorphism threshold of 20%, such that any position with two or 26 more nucleotide frequencies above this threshold was encoded as an ambiguous base using the 27 corresponding IUPAC symbol. Further, we censored all positions with fewer than 50 mapped 28 reads as missing data -this threshold was less stringent than the minimum number of mapped 29 reads (1000) required for positions to be carried over to the SVM analysis, because the objective of 1 the latter was to detect associations with polymorphisms at a minimum frequency of 1%. Since a 2 minimum of 10 mapped reads (1% × 1000) was required to be interpreted as a real polymorphism, 3 the same number of mapped reads was required to influence the consensus sequence at a cutoff of 4 20% (50 reads × 20% = 10 reads). Drug resistance prediction scores on the resulting consensus Subtype and phylogenetic analysis 8 We used the same consensus sequences generated for drug resistance prediction to predict subtypes 9 and reconstruct the phylogeny. We used the SCUEAL algorithm in HyPhy [57] to generate subtype 10 classifications and detect inter-and intra-subtype recombination. Next, we excluded predicted re-11 combinant sequences and sequences that were classified as circulating recombinant forms (CRFs), 12 and generated a multiple sequence alignment from the remaining sequences using MUSCLE (ver- The α-helix that connects the catalytic core domain (CCD) to the C-terminal domain (CTD) of 25 the HIV-1 integrase protein is not resolved in the available DNA bound three-dimensional (3D) 26 structure (PDB ID 5U1C). We therefore modelled the coordinates of the missing α-helix region 27 (a total of 22 amino acids derived from PDB ID 1EX4) into one monomer (chain A) of the orig-28 inal structure (PDB ID 5U1C) using the program MODELLER (version 9.21) [62] to create an type C. The remaining samples were assigned to other inter-subtype recombinants or could not 1 be confidently assigned to a known subtype or circulating recombinant form. We found no sig-2 nificant association between predicted HIV-1 subtypes and RAL-based treatment failure (Fisher's 3 exact test, P = 0.5). Variation among sequences was best explained by the general time reversible (26.9%) were predicted to have high-level resistance to RAL (score ≥ 60). One of these samples 16 (score 120) harbored the major RAL resistance mutation G140A (in 99.12% of reads) in combi-17 nation with the accessory mutation E138K (99.1%). An additional 10 samples carried the major 18 mutation N155H at frequencies between 94.2% and 99.7%, and two samples carried the major 19 RAL resistance mutation T66K (at 93.8% and 62.7%, respectively). Finally, two samples with 20 high RAL resistance scores in this group carried the major mutation Q148R in combination with 21 accessory mutation G163R. This relative lack of expected mutational pathways in the RAL failure the sparse binary encoding approach in [18] so that every sample was represented by a total of 5,760 1 binary variables for 20 amino acids at 288 positions in the HIV-1 integrase reference. This is an 2 unwieldy number of predictor variables for conventional association tests like logistic regression. The entire set of amino acid polymorphisms selected by support vectors for the LT data set 9 are summarized in Supplementary Table S2 . To identify the most promising features from these 10 results, we filtered the features that were selected in at least 40 imputations and where the mean 11 lower 95% confidence limit in odds ratios was greater than 1. ( Supplementary Table S2 ). Only G163R, V151I and T97A were selected in a majority (>80%) 20 of analyses, and in fact were selected for all 50 imputed matrices. Overall, our filtering criteria 21 selected the following polymorphisms in descending order of weight: G163R, V165I, N155H,
22
V151I, I203M, T97A, K211N, A129S, D288E, K240R, Q148K, I135F, C65R, I208L and T218S.
23
The relative locations of these polymorphisms are summarized in Figure 2C . For instance, we 24 observed a cluster of 6 selected polymorphisms within the interval IN 198 to 218, which is distal 25 to both the integrase active site and RAL binding site.
26
The higher frequency threshold (<20%) for the HT data set substantially reduced the effective 27 number of amino acid polymorphisms; as a result, there were fewer features selected in the support 28 vectors (n = 299; Supplementary Table S3 ). Applying the same criteria as above to identify the N155H, G163R, T97A, I208L, I203M and G134N ( Figure 2D ). Of these features, only the primary 1 mutation N155H and secondary mutations T97A and G163R have been previously described. Figure 3 : Summary of intra-host frequencies for known major RAL mutations and two candidate mutations I203M and I208L. Samples from n = 30 RAL failures patients carrying at least one of these mutations are each represented by a set of barplots representing mutation frequencies on the right. The height of each bar is proportional to 1 + log 10 (p) for p ranging from 1% to 100% (see legend in bottom-left). The vertical ordering of samples was determined by a hierarchical clustering analysis, with the corresponding dendrogram displayed on the left. Vertical bars have been added on the left to highlight the subsequent specific pathways.
I203M and I208L confer resistance to INSTIs in vitro 1
Based on these SVM analyses, we selected the novel substitutions I203M and I208L for further 2 investigation, as they appeared in both lists of the most significant features from the LT and HT 3 data sets. Figure 3 contrasts the intra-host frequencies of I203M and I208L in the context of known was propagated on U87.CD4.CXCR4 cells in vitro. We then performed drug susceptibility assays 7 on TZMbl cells exposed to the wild type and mutated HIV-1 and treated with varying concentra-8 tions of RAL and DTG. These experimental results are summarized in Figure 4 . We confirmed 9 that the presence of either I203M or I208L significantly decreased susceptibility to RAL (44.0-10 fold and 54.9-fold, respectively) compared to wild-type virus (EC 50 = 0.32 nM). Furthermore, we 11 found that I203M significantly decreased susceptibility to DTG (111-fold) and that there was no 12 in the RAL-naïve category in the HIVdb database were 5.9% and 5.0%, respectively, suggesting 1 these two mutations are natural polymorphisms that circulate at low frequencies (> 0.5%). We 2 noticed only slight but statistically significant increases in these frequencies in association with 3 the RAL-experienced category in HIVdb (Table 2) . Although we observed more substantial in-4 creases in association with the RAL failure category in our study population ( Figure 5D ). It is however important to stress that these mutations were modeled into a subtype B 22 integrase structure, as structures for other subtypes are not yet available.
23
Discussion
24
The majority of our knowledge on drug resistance mutations (DRMs) in HIV-1 comes from studies 25 of subtype B, even though this subtype represents only a small proportion of infections worldwide.
26
In a previous study [34] , we observed an absence of known DRMs associated with RAL resistance The modelled extended structure (palecyan) is superimposed on chain A to show the missing α-helix where the I208L mutation is located (B) a crystal structure of integrase protein CCD (shown as a green cartoon) bound to the human LEDGEF protein (shown as sticks) (C) the modelled I203M mutant structure (limegreen) of HIV-1 integrase superimposed on the modelled extended wild type structure (greencyan) (D) the modelled I208L mutant structure (aquamarine) of HIV-1 integrase superimposed on the modelled extended wild type structure (greencyan) (E) the modelled I203M and I208M mutant structure (lime) of HIV-1 integrase superimposed on the modelled extended wild type structure (greencyan). All catalytic active site residues are colored purple while the novel mutation sites are colored blue (I203M) and red (I208L) respectively. The know major RAL major resistance mutation sites were colored as follows: T66 (cyan), Y143 (lightgreen), Q148 (green), 155 (orange). These images were generated with PyMOL for patients failing treatment above 1,000 copies/mL, the majority of requests were obtained when 12 viral loads exceed 10,000 copies/mL (averaging 4.8 log 10 copies/mL for first-line treatment failure, 13 and >5.0 log 10 copies/mL for RAL-based/third-line treatment failure) [31, 34] . one-half was converted to cDNA. Given that half of the reaction mixture was used for PCR amplifi-17 cation and sequencing, we would expect at least 850 templates on average to be available for NGS.
18
To evaluate the effect of template resampling on our ability to measure variant frequencies, we 19 can simulate the sampling process assuming that extraction and aliquoting is sampling uniformly 20 at random without replacement, and that sequencing post-amplification is sampling uniformly at 21 random with replacement. For instance, we predict that a variant found in 500 copies/mL (0.5% of the plasma sample) has a 0.03% probability of being sampled to a frequency of 1% or greater un-23 der our experimental conditions (2.5% and 97.5% quantiles = 0.26%, 0.77%; N = 10 6 replicates).
24
Conversely, a variant in 1500 copies/mL (1.5%) would be sampled at 1% or less with probability 25 0.93%. We further note that our multiple imputation across repeated NGS of the same samples 26 would have averaged out some sampling variation.
27
Our NGS analysis of RAL naïve and treatment failure samples confirms results from our previ- ized as a minor or accessory mutation with no evidence of directly reducing susceptibility, and has 17 also been characterized as a natural polymorphism that is observed a substantial frequencies in un-18 treated individuals [77] . We surmise that the over-representation of subtype B in earlier studies of 19 HIV-1 integrase variation may have obscured the major effect of this mutation on INSTI resistance 20 that we have observed in both machine learning and in vitro analyses. In contrast, we have found 21 almost no previous mention of I208L in the HIV-1 drug resistance literature.
22
Another limitation of our study is that our NGS experiments focused specifically on the region including the mutations I203M and I208L with resistance effects that are independent of the known 6 mutations (Figure 3) , implies the existence of a novel and possibly subtype-dependent mechanism 7 of drug resistance that requires further bioinformatic and experimental investigation. 
